THE INVESTOR’S PERSPECTIVE
Ideas, analysis, and opportunities across the world of investing.
Banks earn billions on customer inertia, and stablecoins, AI agents and high-yield apps are all aimed at it. The durable winners will be those who own the customer relationship.
Oncology and technology generate 37% of McKesson's profit from 15% of its sales. A drug wholesaler's mix shift is quietly reshaping the earnings story.
Wells Fargo's Ecolab upgrade highlights a shift from sanitation toward recurring data-center cooling and chip-fab water services. The real question is how much of that compounding story is already priced in.
Office loan delinquencies sit near 12% as hundreds of billions in 2021-vintage debt come due at far higher rates. For long-term investors, maturity schedules and leverage matter more than headline yield.
Credit card balances hit a record $1.29 trillion while October retail sales slowed to their weakest pace in nearly a year. For long-term investors, pricing power and balance-sheet strength matter more than headline spending.
Hot October inflation and talk of a larger December hike pushed the 10-year Treasury to nearly 5%. A higher risk-free rate raises the bar for every long-term holding.
Chains from Burger King to Wendy's are rebuilding recipes instead of piling on discounts. The early results, and the margin costs, say a lot about which brands can compound.
Bond markets are repricing the AI buildout, with CoreWeave yields above 16% and default insurance costs rising even for Nvidia and Amazon. For long-term investors, funding discipline and free cash flow may matter more than growth headlines.
Berkshire jumped 5% in a week the Nasdaq fell 3.4%, erasing its year-long lag. The rally is a reminder of what investors pay for when AI optimism cools.
Global vehicle output is set to stall in 2027 just as prices near record highs and costs keep climbing. Toyota's hybrid-driven upgrade shows which playbooks hold up in a flat market.
Rheinmetall's second guidance cut in three months drove the stock down roughly 46% this year, even as its backlog hit 78 billion euros. The gap between delayed contracts and strong earnings is the real lesson for patient investors.
CVS will split its insurer and PBM from its 9,000 pharmacies by 2028, reversing the $78 billion Aetna deal. The timing, after a 70% rally, raises the question of what each piece is worth.